Advertisement

Topics

Companies Related to "Effect of Maraviroc on Metabolic Function in Obese Subjects (Phase I)" [Most Relevant Company Matches] RSS

09:51 EST 17th February 2019 | BioPortfolio

Here are the most relevant search results for "Effect of Maraviroc on Metabolic Function in Obese Subjects (Phase I)" found in our extensive corporate database of over 50,000 company records.

Showing "Effect Maraviroc Metabolic Function Obese Subjects Phase" Companies 1–25 of 1,800+

Relevant

CogState Ltd

CogState Ltd specializes in the development and commercialization of rapid, computerized tests of cognition (brain function). The tests are sold to pharmaceutical, biotechnology, nutraceutical and functional food companies to quantify the effect of drugs or other interventions on human subjects participating in clinical trials.


Sangamo BioSciences, Inc.

Sangamo BioSciences, Inc. is focused on the research and development of novel DNA-binding proteins for therapeutic gene regulation and modification. The most advanced ZFP Therapeutic(TM) development program is currently in a Phase 2b clinical trial for evaluation of safety and clinical effect in patients with diabetic neuropathy and a Phase 2 trial in ALS. Sangamo also has two Phase 1 clinical tri...

resTORbio, Inc.

resTORbio, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for the treatment of aging-related diseases. resTORbio’s lead program is targeting the target of rapamycin complex 1 (TORC1) pathway to treat aging-related diseases and conditions with an initial focus on conditions caus...


Tricida, Inc.

Tricida, Inc. is a pharmaceutical company focused on the development and commercialization of TRC101, a non-absorbed, orally-administered polymer designed to treat metabolic acidosis in patients with CKD. Metabolic acidosis is a condition commonly caused by CKD that is believed to accelerate the progression of kidney deterioration. Tricida has successfully...

Orasi Medical

Orasi Medical develops products to measure the effect of neurological treatments and track the progression of neurological disorders. Pharmaceutical companies use Orasi Index(TM), the company's flagship product, to reduce costs and improve clinical development of neurological treatments. Orasi's high-resolution measurement of brain function provides a robust, non-invasive and reproducible measure ...

Harbor BioSciences, Inc.

Harbor BioSciences is a development-stage company with two product candidates in clinical trials: Apoptone (HE3235), in the cohort expansion portion of a Phase I/IIa trial of patients with late-stage prostate cancer, and Triolex®, in a Phase IIa trial in obese type 2 diabetes mellitus patients. Apoptone and Triolex represent the lead candidates from Harbor BioSciences' small molecule platform bas...

Hollis-Eden Pharmaceuticals, Inc.

Hollis-Eden Pharmaceuticals is a development-stage company with two product candidates in clinical trials: Apoptone® (HE3235), in the dose-escalation portion of a Phase I/II trial of patients with late-stage prostate cancer, and Triolex®, in a Phase IIa trial in obese type 2 diabetes mellitus patients. Apoptone® and Triolex® represent the lead candidates from Hollis-Eden's small molecule pla...

Midway Pharmaceuticals

Midway Pharmaceuticals is an emerging pharmaceutical company focused on developing proprietary drugs for the treatment of gastrointestinal diseases. The company’s platform technology capitalizes on the finding that certain high molecular weight polymers, taken orally but not systemically absorbed, can inhibit the pathogenic behavior of bacteria in the...

Berzelius Clinical Research Center

Berzelius Clinical Research Center AB (BCRC) is a unique Site Management Organisation specialised in clinical conduct of Phase 0/I/II studies and the ideal partner for Contract Research Organisations (CRO) and pharmaceutical companies. BCRC has a hospital based well-equipped clinical pharmacology unit. Having a fully trained critical care staff enables easy setup of invasive techniques and procedu...

POXEL S.A.

Poxel uses its development expertise in metabolism to advance a pipeline of drug candidates focused on the treatment of metabolic disorders, including type 2 diabetes and non-alcoholic steatohepatitis (NASH). We have successfully completed the Phase 2 clinical program for our first-in-class lead product, Imeglimin, which targets mitochondrial dysfunction, ...

SiDMAP, LLC

SiDMAP provides flux-based, metabolic profiling services to pharmaceutical, biotech and research organizations seeking to enhance their drug development processes, and develop further insights into a drug’s mechanism of action and disease states. SiDMAP’s unique tracer technology measures metabolic pathway flux to gain unique insights into cell f...

Eminent effect

The eminent effect is a consultancy aiming to stand out from the crowd in tackling many of today’s people and business challenges. The company offers organisation specific training, development, sales/marketing and interim management solutions not off the shelf packages.Primarily working within the NHS, Pharmaceutical and Biotechnology sectors, the eminent effect personnel can offer experience g...

OcuSciences, Inc.

OcuSciences, Inc., is a clinical-stage biotechnology company developing retinal imagers to identify metabolic dysfunction occurring in the retina for the detection of early disease. Its flagship device, the OcuMet Beacon, is being developed to automatically and non-invasively assess retinal metabolic function by detecting the degree of flavoprotein fluores...

Essentialis, Inc.

Essentialis, Inc. is a pharmaceutical company based in Carlsbad, CA. The Company's products are targeted at the ATP-sensitive potassium channel, a metabolically-regulated membrane protein whose modulation has the potential to impact a wide range of cardiovascular and metabolic diseases. The Company's lead product, DCCR, is set to commence pivotal studies in subjects with very high triglycerides...

Synapse BV

Synapse BV is a working group within the Cardiovascular Research Institute Maastricht (CARIM) as well as a company within the Maastricht University Holding. It carries out developmental research in the field of the (patho-)physiology of haemostasis and thrombosis, operating in the niche between biochemistry and molecular biology on the one side and pharmaceutical- and clinical sciences on the othe...

CEL-SCI Corporation CEL-SCI Corporation

CEL-SCI's work is focused on finding the best way to activate the immune system to fight cancer and infectious diseases. Its lead investigational immunotherapy, Multikine* (Leukocyte Interleukin, Injection), is currently being studied in a pivotal Phase 3 clinical trial as a potential neoadjuvant treatment for patients with squamous cell carcinoma of the h...

Pharmacon Research GmbH

Pharmacon Research is an independent contract research organization (CRO) with headquarters in Berlin and clinical sites in Prague, Warsaw, Bratislava and Budapest. Founded in 1992 by the management of a successful Phase I unit, Pharmacon Research focuses on specific Phase I studies in patients and symptomatic subjects and on early Phase II studies (dose finding, proof of concept). Irrespective of...

METabolic EXplorer S.A.

METabolic EXplorer develops and applies cutting edge tools of biotechnology to design new biosynthetic pathways for the efficient and cost-effective production of valuable chemicals.METabolic EXplorer provides the chemical and life science industry with cost-effective innovative solutions for the manufacturing of their chemicals by fermentation.METabolic EXplorer creates new whole-cell biotransfor...

Xention Discovery Ltd

Ion channels influence a multitude of physiological processes from the generation of electrical activity in nerves involved in sensory and motor functions in the brain, to the control of contractile activity in heart, skeletal, and smooth muscle, to nutrient uptake, hormone secretion, cell replication and development and immune cell function.The importance of ion channels in disease pathology is w...

Metabolic Solutions Development Company

Metabolic Solutions Development Company (www.msdrx.com), based in Kalamazoo, Mich., is developing innovative therapeutics using a different pharmacological path to treat type 2 diabetes and related metabolic diseases. This new approach seeks to improve the efficacy of treatment and free patients from the adverse side effects of current treatments, including edema and weight gain.

DeveloGen

DeveloGen is a biopharmaceutical company engaged in the discovery and development of novel therapeutic drugs for the treatment of metabolic disorders. The Company has a broad and innovative pipeline from lead discovery to phase III clinical development.

Speedel

Speedel is a biopharmaceutical company that seeks to create value for patients, partners and investors by developing innovative therapies for cardiovascular and metabolic diseases. Speedel is a world leader in renin inhibition, a promising new approach with significant potential for treating cardiovascular diseases. Our lead product candidate SPP100 (Aliskiren), the first-in-class renin inhibitor,...

Complexa, Inc.

Complexa, Inc. is a platform biopharmaceutical company researching and developing endogenous human cell signaling technologies targeting an array of prevalent inflammatory and metabolic diseases. The company’s proprietary technology involves the synthesis and therapeutic applications of endogenous nitro-fatty acids (NFAs) and additional structure/func...

Cenduit, LLC

Cenduit is a privately owned joint venture of Quintiles and Fisher Clinical Services, part of Thermo Fisher Scientific. Cenduit has successfully deployed IRT solutions in over 650 clinical studies. Cenduit’s IRT solution is currently being used in Phase I through Phase IV clinical trials by over 16,000 sites in 78 countries, to enroll more than 220,00...

BioMedica Inc.

Oxford BioMedica (LSE: OXB) is a biopharmaceutical company specialising in the development of novel gene-based therapeutics with a focus on the areas of oncology and neurotherapy. The Company was established in 1995 as a spin out from Oxford University, and is listed on the London Stock Exchange.Oxford BioMedica’s products use genes as the mediators of a therapeutic effect and/or immune response...


More From BioPortfolio on "Effect of Maraviroc on Metabolic Function in Obese Subjects (Phase I)"

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks